Can Transdermal Nicotine Improve MCI?

Share on FacebookTweet about this on TwitterShare on LinkedIn

In non-smoking patients with amnestic mild cognitive impairment (MCI), 6 months of transdermal nicotine (15 mg/day) appear to improve cognitive test performance, but not clinical global impressions of change. A small study found that transdermal nicotine was associated with improvements in attention, memory, psychomotor speed, and patient/informant rating of cognitive improvement in those with MCI.

Abstract: Neurology, January 10, 2012.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × four =